I think Takeda's Alofisel® sales / royalties will be interesting as time goes on more so than JCR's Temcell® growth.... Temcell® 's growth will probably taper off during the same period unless they start using it to treat other medical conditions outside of GVHD ?
I would also add that Alofisel® is slowly being released internationally as approvals are obtained whereas in comparison to Temcell® which is currently limited to one country - Japan
MSB $1 Party, page-682
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.005(0.52%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 98.5¢ | 91.5¢ | $4.743M | 4.999M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 123302 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |